|
||||||||||||||||||||||||||||||||||||
| [
Contents
] [ INDEX ]
|
||||||||||||||||||||||||||||||||||||
| UDK 616.248-085.451.3 |
ISSN 0350-2899, 37(2012) br.1 p.20-24 |
|||||||||||||||||||||||||||||||||||
|
Original paper Effects of salmeterol xinafoate/fluticasone propionate in achieving total control in patients with bronchial asthma (Efekti salmeterol ksinafoata/flutikazon propionata na postizanje potpune kontrole kod obolelih od bronhijalne astme) Dejan Dimić (1), J. Menković (2), Lj.Timotijević(1) (1) Gradski zavod za bolesti pluća i TBC Beograd, (2) Dom zdravlja Zemun |
||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
| Summary: Bronchial asthma, as a chronic inflammation of respiratory paths, is one of the leading causes of chronic morbidity and mortality in the world, with a tendency towards increasing prevalence, especially among young people. Given the nature of the disease, one of the most effective therapeutic measures in the treatment of bronchial asthma is the use of fixed combination of inhalatory corticosteroids (ICS) and long acting beta 2 agonist. The primary goal was to determine the efficiency of fixed combination Salmeterol xinafoate and Fluticasone propionate in achieving complete control in patients with asthma. For that purpose, in the period 1st January 2008 – 31st December 2010, 128 patients who at the start of follow-up suffered from partly controlled asthma, 25–45 years of age, non-smokers, were treated only with a fixed combination of Salmeterol xinafoate (50 mcg) and Fluticasone propionate (250 mcg) with the use of short-acting beta 2 agonist if necessary, for the period of 3 months. In that period the indicators of life quality and values of lung function were monitored. The average age of test group was 28.76 and BMI was 23.02. At baseline, daily symptoms more than twice a week had 91 (71.1%) patients, after a month 49 (38.3%), after two months 22 (17.2%), after three months 11(8.6%). Of restricted activity at baseline complained 69 (53.9%), after a month 51 (39.8%), after two months 29 (22.7%), after three months 13 (10.2). Nocturnal symptoms at baseline had 76 (59.4%), after a month 42 (32.8%), after 2 months 20 (15.6%), after 3 months 10 (7.8%). The need to use short-acting beta 2 agonist more than twice a week at baseline had 102 (79.7%) patients, after a month 57 (44.5%), after 2 months 38 (29.7%), after three months 10 (7.8%) patients. The number of days without symptoms in the last month at baseline was 2.3 (7.7%), after a month 17.4 (58%), after 2 months 27.6 (90%), after 3 months 28.6 (95.3%). Mean value of FEV1 (Actvated value/Foreseeen value [%]) at baseline was 63.5, after a month 77.1(increase of 21.4%), after 2 months 80.4(increase of 26.6%), after 3 months 91.2 (increase of 43.6%). The mean value of PEF (Actvated value/Foreseeen value [%]) at the beginning was 70.4, after a month 84.2(increase of 19.6%), after 2 months 87.8(increase of 24.7%), after 3 months 91.3 (increase of 29.7%). The mean value of FEF75 at the beginning was 46.7, after a month 63.6 (increase of 36.2%), after 2 months 79.8(increase of 70.9%), after 3 months 90.3 (increase of 93.4%). The mean value of FEF50 at the beginning of monitoring was 51.5, after a month 70.6(increase of 37.1%), after 2 months 85.3(increase of 65.6%), after 3 months 90.1 (increase of 74.9%). The mean value of FEF25 at the beginning of monitoring was 34.2, after a month 61.3(increase of 79.2%), after 2 months 70.6(increase of 106.4%), after 3 months 87.3 (increase of 155.3%). On the basis of the results we concluded that the use of fixed combination Salmeterol xinafoate/Fluticasone propionate improves the quality of life and lung function in patients with asthma, as confirmed by statistical evaluation. Key words: Salmeterol xinafoate/Fluticasone propionate, total control, asthma Napomena:
kompletan tekst rada na srpskom jeziku |
||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
|
Corresponding Address: Dejan Dimić Bulevar Arsenija Čarnojevića 191/1 11070 Novi Beograd Tel : 063/87 29 110 e-mail : dejandimic61@yahoo.com |
Paper received:
22. 08. 2011 Paper accepted: 24. 02. 2012 Paper Internet issues: 10. 06. 2012 |
|||||||||||||||||||||||||||||||||||
| [
Contents
] [ INDEX ]
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
